Canada markets open in 3 hours 29 minutes

BioSyent Inc. (RX.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
8.70+0.01 (+0.12%)
At close: 02:31PM EDT
Full screen
Previous Close8.69
Open8.69
Bid8.69 x 0
Ask8.70 x 0
Day's Range8.64 - 8.70
52 Week Range7.03 - 9.26
Volume2,202
Avg. Volume4,916
Market Cap101.026M
Beta (5Y Monthly)0.93
PE Ratio (TTM)16.42
EPS (TTM)0.53
Earnings DateMay 24, 2024 - May 28, 2024
Forward Dividend & Yield0.18 (2.07%)
Ex-Dividend DateFeb 28, 2024
1y Target Est9.00
  • GlobeNewswire

    BioSyent Announces Grant of Restricted Share Units

    MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to certain directors, officers, management, and employees of the Company pursuant to the Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs will fully vest within three years on the third anniversary of the applicable grant date. About BioSyent Inc. Listed on the TSX

  • GlobeNewswire

    BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023

    MISSISSAUGA, Ontario, March 13, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended December 31, 2023. Key highlights include: (CAD)Q4 2023% Change vs. Q4 2022FY 2023% Change vs. FY 2022Canadian Pharma Sales7,989,09810%29,554,89913%International Pharma Sales54,750-54%1,047,74753%Total Company Sales8,273,68611%31,590,30213%EBITDA11,650,3015%7,926,4787%Net Income After Taxes (NIAT)1,450,79121

  • GlobeNewswire

    BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024

    MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2023 on Wednesday, March 13th after market hours. A presentation on the Company’s fourth quarter and full year 2023 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exc